EDTA Enhances Vancomycin and ROS Efficacy Against VISA Infections
Overview
Vancomycin-intermediate Staphylococcus aureus (VISA) exhibits metabolic adaptations that reduce susceptibility to vancomycin and reactive oxygen species (ROS). This study demonstrates that ethylenediaminetetraacetic acid (EDTA) potentiates vancomycin efficacy by enhancing ROS-mediated bacterial killing both in vitro and in vivo.
Background
VISA strains pose a significant clinical challenge due to their antibiotic tolerance linked to metabolic shifts, including downregulation of Krebs cycle enzymes and increased anaerobic metabolism. Standard susceptibility testing in nutrient-rich media often fails to capture these adaptations, leading to treatment failures. Iron-mediated ROS production plays a key role in bacterial killing, and chelators like EDTA can increase ROS bactericidal activity by solubilizing iron. This study investigates EDTA as an adjunct to vancomycin to overcome VISA tolerance mechanisms.
Data Highlights
Condition
Effect on VISA Killing
Vancomycin alone
Limited efficacy against VISA
EDTA alone
Improved H2O2-mediated killing
Vancomycin + EDTA
Enhanced killing by H2O2 and neutrophils; improved in vivo efficacy
Vancomycin + EDTA + ROS scavengers (thiourea or BHA)
VISA strains downregulate Krebs cycle enzymes and genes related to iron and ROS resistance under physiological conditions.
EDTA enhances hydrogen peroxide-mediated killing of VISA, an effect reversed by hydroxyl radical scavengers.
Combination of EDTA and vancomycin significantly improves neutrophil-mediated killing of VISA, dependent on ROS activity.
In a murine bacteremia model, EDTA potentiates vancomycin efficacy against VISA infections.
EDTA likely promotes ROS-mediated bacterial killing by increasing iron availability for Fenton chemistry, targeting VISA metabolic adaptations.
Clinical Implications
Adjunctive use of EDTA with vancomycin may improve treatment outcomes for infections caused by VISA by enhancing ROS-mediated bacterial killing. This strategy addresses metabolic tolerance mechanisms not detected by standard susceptibility testing and could be particularly valuable where alternative antibiotics are limited. Incorporating EDTA could optimize vancomycin efficacy in complicated staphylococcal infections.
Conclusion
EDTA potentiates vancomycin activity against VISA by enhancing susceptibility to ROS-mediated killing, overcoming key bacterial metabolic adaptations. These findings support further exploration of EDTA as a therapeutic adjunct to improve clinical management of antibiotic-tolerant staphylococcal infections.
References
Study Authors/Antimicrobial Resistance Major Article -- Ethylenediaminetetraacetic Acid Potentiates the Efficacy of Vancomycin and Reactive Oxygen Species Against Vancomycin-Intermediate Staphylococcus aureus
